Posatirelin for the treatment of late-onset alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid
L. Parnetti
Bok Engelsk
| Utgitt | L Parnetti Univ Perugia Via Eugubina 42 I-06
|
|---|---|
| Opplysninger | Introduction - Posatirelin (L-pyro-2-amindadipyl-1-leucil-1- prolinamide) a new synthetic tripeptide with cholinergic, catecholaminergic and neurotrophic properties, was investigated in the treatment of Alzheimer's disease. Material and methods - A multicentre, double-blind study vs citicoline (reference drug) and ascorbic acid (inactive drug) was carried out in elderly patients suffering from late-onset Alzheimer's disease. The once daily intramuscular treatment lasted for three months followed by one-month oral treatment with a placebo. Subscales and factors of GBS (Gottfries-Brane-Steen) Rating Scale were identified as primary measures for efficacy assessment, Results - At the end of the treatment, GBS subscale and factor scores assessing intellectual and emotional impairments, orientation and memory, ability to perform activities of daily living, depression-anxiety, attention and motivation were improved in the posatirelin group, showing significant differences with respect to the citicoline and/or ascorbic acid groups, Tolerability was good in all groups. Conclusions - The improvement in the GBS Rating Scale scores observed in the posatirelin group is clinically relevant. It is worth verifying the drug- induced functional improvements, in further studies with large samples.
|
| Emner | |
| ISSN |
